BiomX is developing both natural and engineered phage cocktails designed to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as cystic fibrosis, inflammatory bowel disease, atopic dermatitis and colorectal cancer. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.
Location: Israel, Center District, Ness Ziona
Employees: 51-200
Total raised: $56M
Founded date: 2015
Investors 5
| Date | Name | Website |
| - | Takeda Ven... | takeda.com |
| - | Baruch Fut... | baruch.vc |
| - | OrbiMed | orbimed.co... |
| - | AMR Action... | amractionf... |
| - | SymBiosis | symbiosis.... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 21.02.2019 | Series B | $32M | - |
| 15.05.2017 | Series A | $24M | OrbiMed |
Mentions in press and media 20
| Date | Title | Description |
| 22.11.2024 | Converge Bio: The Future of Drug Discovery Speaks the Language of Life | In the world of pharmaceuticals, time is a luxury few can afford. The process of drug discovery is a labyrinthine journey, often taking a decade or more, with costs spiraling past a billion dollars. Yet, a new player has entered the arena, ... |
| 22.11.2024 | Converge Bio raises $5.5M to expedite drug discovery, development with GenAI | Photo: mediaphotos/Getty Images Converge Bio has raised $5.5 million in seed funding led by TLV Partners. WHAT IT DOES Converge Bio is a generative AI hub for Biotech and Pharma that allows the accelerated discovery and development of drugs... |
| 21.11.2024 | Converge Bio Raises $5.5M to Accelerate Drug Discovery with GenAI | What You Should Know: – Converge Bio, a generative AI platform for accelerated drug discovery and development, today announced it has raised $5.5 million in seed funding, led by TLV Partners. – Converge Bio’s platform uses large language mo... |
| 20.11.2024 | Generative AI drug discovery hub Converge Bio raises $5.5M to understand the ‘language of biology’ Your vote of support is important to us and it helps us keep the content FREE. One click below suppor... | Drug discovery startup Converge Bio Inc. said today it has closed on a $5.5 million seed round of funding to help biotech and pharmaceutical companies develop more effective drugs at faster speeds by leveraging generative artificial intelli... |
| 26.05.2024 | Stress and Skin: A Complex Relationship | Stress can be a silent killer, not just for your mental health but also for your skin. Dermatologists reveal the hidden connection between stress and skin problems, shedding light on how our emotions can manifest physically. Stress is like ... |
| 20.05.2024 | Studies Show Linked Biological Pathways Driving Skin Inflammation | NEW YORK, May 20, 2024 /PRNewswire/ -- A certain biological pathway, a set of linked reactions in the body, drives the inflammation seen in the skin disease psoriasis, a new study finds. The work could lead to improved therapies for all inf... |
| 18.03.2024 | BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million Financing | - |
| 06.03.2024 | BiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics and Concurrent $50 Million Financing | - |
| 26.07.2021 | BiomX Inc. Announces $15 Million Registered Direct Offering | NESS ZIONA, Israel, July 26, 2021 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic ba... |
| 24.05.2021 | BIOMX INC. BiomX : Earnings Document | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended March 31, 2021 TRANSITION REPORT PURS... |
Show more